Phase III
There are dollar signs in the treatment of nonalcoholic steatohepatitis (NASH). The market is pegged to hit $25 billion by 2026 and companies are flooding the developmental pipeline with potential treatments for a disease that has no approved therapies in the United States.
A day after Illinois-based Aptinyx strengthened its relationship with pharma giant Allergan, the company is now eying an $80 million initial public offering of stock on the Nasdaq Exchange.
Shares of Cara Therapeutics are soaring this morning after the company announced it secured $70 million in cash as part of a licensing agreement with Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP) for the company’s chronic kidney disease treatment Korsuva.
Verrica Pharmaceuticals, headquartered in West Chester, Pennsylvania, is launching an initial public offering (IPO), hoping to raise $86 million.
Merck & Co’s anti-PD-1 therapy Keytruda dazzled in its pivotal Phase III KEYNOTE-407 trial.
Allergan has exercised an option to acquire an oral small molecule compound from Illinois-based Aptinyx, a spinout of Naurex, Inc., which the Irish company acquired in 2015. The company will use it as a complement to a Phase III depression treatment.
Dova Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved its Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
Shares of newly dubbed Sesen Bio (formerly Eleven Biotherapeutics) have plunged 23 percent after the company released positive, three-month data from its ongoing Phase III high-grade non-muscle invasive bladder cancer (NMIBC) trial.
Nabriva Therapeutics reported positive topline results from its Phase III clinical trial of oral lefamulin compared to oral moxifloxacin in adults with moderate community-acquired bacterial pneumonia (CABP).
Genentech’s hemophilia treatment Hemlibra continues to demonstrate its efficacy in treating patients. New late-stage data presented at World Federation of Hemophilia 2018 World Congress shows the drug significantly reduced treated bleeds in a broad patient population in two separate studies.
PRESS RELEASES